Search

Meet Michaela Gruber, our December volunteer of the month

Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.

Read more

Connecting experts on inherited anemias and iron defects in Budapest

October 12-14, 2023 – Budapest, Hungary 

Meeting Chairs: 
Ali Taher, American University of Beirut Medical Center, Beirut, Lebanon 

Achille Iolascon, University Federico II of Naples, Naples, Italy 

In October 2023 EHA and the Specialized Working Group (SWG) on Red Cell and Iron hosted a…

Read more

Meet our first Physician Scientist Research Grant winner

In 2018 the Physician Scientist Research Grant was awarded for the first time.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

ATMPs and CAR-T: the uptake challenge

Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.

Read more

Open Access: the ‘Plan S’

 

Research and academic groundwork funded with public means should be free and open to everyone. That is the principle behind Open Access that was formulated in 2003 in the Berlin Declaration.

Read more